{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:36:17Z","timestamp":1790339777953,"version":"4.1.0"},"reference-count":150,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"am","delay-in-days":391,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.gofs.2019.01.003","type":"journal-article","created":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T01:28:11Z","timestamp":1550539691000},"page":"197-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Chirurgie des cancers avanc\u00e9s de l\u2019ovaire. Article r\u00e9dig\u00e9 sur la base de la recommandation nationale de bonnes pratiques cliniques en canc\u00e9rologie intitul\u00e9e \u00ab\u00a0Conduites \u00e0 tenir initiales devant des patientes atteintes d\u2019un cancer \u00e9pith\u00e9lial de l\u2019ovaire\u00a0\u00bb \u00e9labor\u00e9e par FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY sous l\u2019\u00e9gide du CNGOF et labellis\u00e9e par l\u2019INCa"],"prefix":"10.1016","volume":"47","author":[{"given":"G.","family":"Ferron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Narducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Pouget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9149-1663","authenticated-orcid":false,"given":"C.","family":"Touboul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib0755","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.ygyno.2006.06.025","article-title":"Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer\u00a0: a meta-analysis","volume":"103","author":"Bristow","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.gofs.2019.01.003_bib0760","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.gofs.2019.01.003_bib0765","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1093\/annonc\/mdt237","article-title":"Quality indicators in ovarian cancer surgery\u00a0: report from the French Society of Gynecologic Oncology (Societe francaise d\u2019oncologie gynecologique, SFOG)","volume":"24","author":"Querleu","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gofs.2019.01.003_bib0770","article-title":"Optimal primary surgical treatment for advanced epithelial ovarian cancer","volume":"8","author":"Elattar","year":"2011","journal-title":"Cochrane Database of Syst Rev"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.003_bib0775","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/IGC.0000000000000597","article-title":"Surgical Techniques for diaphragmatic resection during cytoreduction in advanced or recurrent ovarian carcinoma: a systematic review and meta-analysis","volume":"26","author":"Bogani","year":"2016","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib0780","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ygyno.2013.05.040","article-title":"Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis","volume":"130","author":"Chang","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.gofs.2019.01.003_bib0785","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1200\/JCO.2009.25.3617","article-title":"Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials","volume":"28","author":"du Bois","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib0790","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.gofs.2019.01.003_bib0795","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s10147-011-0223-5","article-title":"Comparison between serous and non-serous ovarian cancer as a prognostic factor in advanced epithelial ovarian carcinoma after primary debulking surgery","volume":"16","author":"Hosono","year":"2011","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib0800","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ygyno.2007.09.020","article-title":"Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma","volume":"108","author":"Chi","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2019.01.003_bib0805","article-title":"Centralisation of services for gynaecological cancer","volume":"3","author":"Woo","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib0810","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2012.07.023","article-title":"Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials","volume":"49","author":"Mahner","year":"2013","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib0815","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ygyno.2006.01.035","article-title":"Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer","volume":"102","author":"Paulsen","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.gofs.2019.01.003_bib0820","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ejso.2006.02.013","article-title":"The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma","volume":"32","author":"Rosa","year":"2006","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"10.1016\/j.gofs.2019.01.003_bib0825","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/AOG.0b013e31826981de","article-title":"Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer","volume":"120","author":"Wright","year":"2012","journal-title":"Obstet Gynecol"},{"issue":"8","key":"10.1016\/j.gofs.2019.01.003_bib0830","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2014.56.3106","article-title":"Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182","volume":"33","author":"Horowitz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib0835","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ygyno.2007.02.026","volume":"106","author":"Wimberger","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib0840","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","article-title":"Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm","volume":"114","author":"Chi","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.gofs.2019.01.003_bib0845","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ajog.2007.10.495","article-title":"Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer","volume":"197","author":"Aletti","year":"2007","journal-title":"Am J Obstet Gynecol"},{"issue":"8","key":"10.1016\/j.gofs.2019.01.003_bib0850","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1471-0528.2009.02214.x","article-title":"Pulmonary morbidity of diaphragmatic surgery for stage III\/IV ovarian cancer","volume":"116","author":"Chereau","year":"2009","journal-title":"BJOG"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib0855","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ygyno.2007.08.003","article-title":"Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: a case-control study","volume":"107","author":"Salani","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib0860","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ygyno.2016.12.019","article-title":"En-bloc resection of the pelvis (EnBRP) in patients with stage IIIC-IV ovarian cancer: a 10\u00a0steps standardised technique. Surgical and survival outcomes of primary vs. interval surgery","volume":"144","author":"Tozzi","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib0865","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ygyno.2009.11.031","article-title":"\u201cSurgical Apgar Score\u201d predicts postoperative complications after cytoreduction for advanced ovarian cancer","volume":"116","author":"Zighelboim","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.gofs.2019.01.003_bib0870","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jamcollsurg.2009.01.006","article-title":"Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience","volume":"208","author":"Aletti","year":"2009","journal-title":"J Am Coll Surg"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib0875","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ygyno.2010.05.025","article-title":"The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm","volume":"118","author":"Bristow","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.003_bib0880","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ygyno.2016.05.025","article-title":"Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival \u2013 A population-based cohort study","volume":"142","author":"Dahm-Kahler","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib0885","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ygyno.2016.01.025","article-title":"Primary surgical cytoreduction in advanced ovarian cancer: an outcome analysis within the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group","volume":"140","author":"Greggi","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib0890","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ygyno.2011.02.014","article-title":"Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer","volume":"121","author":"Harter","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.gofs.2019.01.003_bib0895","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ejso.2013.05.011","article-title":"Comparison of optimal cytoreduction rates in emergency versus non-emergency admissions for advanced ovarian cancer: a multi-institutional study","volume":"39","author":"Mangili","year":"2013","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib0900","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2009.12.033","article-title":"Quality of care in advanced ovarian cancer: the importance of provider specialty","volume":"117","author":"Mercado","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.gofs.2019.01.003_bib0905","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/ijgc-00009577-200602001-00002","article-title":"Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals","volume":"16","author":"Paulsen","year":"2006","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib0910","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ygyno.2013.07.001","article-title":"Surgical outcomes and national comprehensive cancer network compliance in advanced ovarian cancer surgery in a low volume military treatment facility","volume":"131","author":"Phippen","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib0915","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ygyno.2012.03.044","article-title":"Outcome of immediate re-operation or interval debulking after chemotherapy at a gynecologic oncology center after initially incomplete cytoreduction of advanced ovarian cancer","volume":"126","author":"Grabowski","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib0920","first-page":"274","article-title":"Evaluation of residual tumor locations in advanced ovarian cancer patients after incomplete primary cytoreduction","volume":"36","author":"Grabowskil","year":"2015","journal-title":"Eur J Gynaecol Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib0925","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ijgc-00009577-200501000-00004","article-title":"The second-look operation improves survival in suboptimally debulked stage III ovarian cancer patients","volume":"15","author":"Rahaman","year":"2005","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib0930","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ygyno.2016.09.005","article-title":"Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: an NRG Oncology\/Gynecologic Oncology Group study","volume":"143","author":"Rose","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib0935","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.AOG.0000192407.04428.bb","article-title":"Aggressive surgical effort and improved survival in advanced-stage ovarian cancer","volume":"107","author":"Aletti","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib0940","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.tjog.2016.04.010","article-title":"Posterior pelvic exenteration and retrograde total hysterectomy in patients with locally advanced ovarian cancer: clinical and functional outcome","volume":"55","author":"Berretta","year":"2016","journal-title":"Taiwan J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.003_bib0945","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2006.03.051","article-title":"What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?","volume":"103","author":"Chi","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.003_bib0950","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejso.2008.01.005","article-title":"Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203\u00a0stage IIIC and IV patients","volume":"35","author":"Colombo","year":"2009","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"10.1016\/j.gofs.2019.01.003_bib0955","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.ejso.2010.09.008","article-title":"Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360\u00a0consecutive patients","volume":"36","author":"Fotopoulou","year":"2010","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"10.1016\/j.gofs.2019.01.003_bib0960","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/IGC.0b013e31826a3559","article-title":"Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study","volume":"22","author":"Luyckx","year":"2012","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.003_bib0965","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ygyno.2010.07.032","article-title":"Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Single institution experience","volume":"119","author":"Peiretti","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2019.01.003_bib0970","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1186\/s12885-015-1525-1","article-title":"Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study","volume":"15","author":"Ren","year":"2015","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib0975","first-page":"727","article-title":"Prognostic factors for surgical outcome and survival in 447\u00a0women treated for advanced (FIGO-stages III\u2013IV) epithelial ovarian carcinoma","volume":"30","author":"Skirnisdottir","year":"2007","journal-title":"Int J Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib0980","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ygyno.2012.04.014","article-title":"Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancer","volume":"126","author":"Tanner","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.003_bib0985","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2015.12.007","article-title":"Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV","volume":"140","author":"Ataseven","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib0990","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ygyno.2009.11.022","article-title":"The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum","volume":"116","author":"Zivanovic","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib0995","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ygyno.2015.03.043","article-title":"Predictors of postoperative morbidity after cytoreduction for advanced ovarian cancer: Analysis and management of complications in upper abdominal surgery","volume":"137","author":"Benedetti Panici","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib1000","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2010.05.031","article-title":"The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas","volume":"119","author":"Chi","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib1005","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ygyno.2009.11.023","article-title":"Upper abdominal surgery in advanced and recurrent ovarian cancer: role of diaphragmatic surgery","volume":"116","author":"Fanfani","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib1010","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1245\/s10434-009-0787-8","article-title":"Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer","volume":"17","author":"Kommoss","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.gofs.2019.01.003_bib1015","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.21873\/anticanres.11025","article-title":"Diaphragmatic surgery in advanced ovarian, tubal and peritoneal cancer. A 7-year retrospective analysis of the tumor bank ovarian cancer network","volume":"36","author":"Muallem","year":"2016","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib1020","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00404-014-3446-7","article-title":"Success rate and safety of tumor debulking with diaphragmatic surgery for advanced epithelial ovarian cancer and peritoneal cancer","volume":"291","author":"Saitou","year":"2015","journal-title":"Arch Gynecol Obstet"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib1025","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ygyno.2015.12.004","article-title":"Diaphragmatic peritonectomy vs. full thickness resection with pleurectomy during Visceral-Peritoneal Debulking (VPD) in 100\u00a0consecutive patients with stage IIIC-IV ovarian cancer: a surgical-histological analysis","volume":"140","author":"Soleymani Majd","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.003_bib1030","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejca.2010.08.020","article-title":"Comparison of diaphragmatic surgery at primary or interval debulking in advanced ovarian carcinoma: an analysis of 163\u00a0patients","volume":"47","author":"Tsolakidis","year":"2011","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib1035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00404-004-0657-3","article-title":"The feasibility and morbidity of distal pancreatectomy in extensive cytoreductive surgery for advanced epithelial ovarian cancer","volume":"272","author":"Yildirim","year":"2005","journal-title":"Arch Gynecol Obstet"},{"issue":"6","key":"10.1016\/j.gofs.2019.01.003_bib1040","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1097\/IGC.0b013e3182571479","article-title":"Splenectomy as part of primary cytoreductive surgery for advanced ovarian cancer: a retrospective cohort study","volume":"22","author":"Zapardiel","year":"2012","journal-title":"Int J Gynecol Cancer"},{"issue":"13","key":"10.1016\/j.gofs.2019.01.003_bib1045","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1245\/s10434-012-2446-8","article-title":"Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer","volume":"19","author":"Chang","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.003_bib1050","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejso.2010.10.004","article-title":"Morbidity of diaphragmatic surgery for advanced ovarian cancer: retrospective study of 148\u00a0cases","volume":"37","author":"Chereau","year":"2011","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"10.1016\/j.gofs.2019.01.003_bib1055","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/IGC.0b013e31824b403d","article-title":"Does significant medical comorbidity negate the benefit of up-front cytoreduction in advanced ovarian cancer?","volume":"22","author":"Ferriss","year":"2012","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib1060","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejca.2009.10.017","article-title":"Prediction of 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer","volume":"46","author":"Gerestein","year":"2010","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib1065","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ygyno.2017.06.007","article-title":"The impact of type and number of bowel resections on anastomotic leakage risk in advanced ovarian cancer surgery","volume":"146","author":"Grimm","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib1070","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/01.AOG.0000257117.78230.0f","article-title":"Supracervical hysterectomy in patients with advanced epithelial ovarian cancer","volume":"109","author":"Milam","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.003_bib1075","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ygyno.2012.04.030","article-title":"Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes","volume":"126","author":"Peiretti","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib1080","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ejso.2015.12.001","article-title":"Total rectosigmoidectomy versus partial rectal resection in primary debulking surgery for advanced ovarian cancer","volume":"42","author":"Plotti","year":"2016","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"10.1016\/j.gofs.2019.01.003_bib1085","doi-asserted-by":"crossref","first-page":"e39415","DOI":"10.1371\/journal.pone.0039415","article-title":"Multi-center evaluation of post-operative morbidity and mortality after optimal cytoreductive surgery for advanced ovarian cancer","volume":"7","author":"Rafii","year":"2012","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.gofs.2019.01.003_bib1090","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1097\/IGC.0b013e318265d358","article-title":"Comparison of morbidity and survival between primary and interval cytoreductive surgery in patients after modified posterior pelvic exenteration for advanced ovarian cancer","volume":"22","author":"Revaux","year":"2012","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib1095","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ygyno.2017.07.136","article-title":"Survival and safety associated with aggressive surgery for stage III\/IV epithelial ovarian cancer: a single institution observation study","volume":"147","author":"Tate","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib1100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2013.07.086","article-title":"The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma \u2013 analysis of patient data in the prospective OVCAD study","volume":"131","author":"Hofstetter","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.gofs.2019.01.003_bib1105","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.003_bib1110","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ygyno.2010.12.328","article-title":"Celiac lymph node resection and porta hepatis disease resection in advanced or recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer","volume":"121","author":"Martinez","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2019.01.003_bib1115","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/j.ejso.2010.06.006","article-title":"Patterns of care in surgery for ovarian cancer in Europe","volume":"36","author":"Verleye","year":"2010","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.003_bib1120","first-page":"60","article-title":"Improved 8-year survival for patients with stage IIIc ovarian cancer operated on at teaching hospitals: population-based study in Norway 2002","volume":"5","author":"Paulsen","year":"2013","journal-title":"Clin Ovarian Other Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib1125","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ygyno.2009.08.025","article-title":"Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes","volume":"115","author":"Bristow","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2019.01.003_bib1130","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/IGC.0b013e31819915cb","article-title":"Influence of department volume on survival for ovarian cancer: results from a prospective quality assurance program of the Austrian Association of Gynecologic Oncology","volume":"19","author":"Marth","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.gofs.2019.01.003_bib1135","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/cncr.22604","article-title":"Predictors of comprehensive surgical treatment in patients with ovarian cancer","volume":"109","author":"Goff","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib1140","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2007.13.1953","article-title":"Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"26","author":"Winter","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib1145","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ygyno.2006.11.025","article-title":"Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease","volume":"105","author":"Hou","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib1150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2013.07.093","article-title":"Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction?","volume":"131","author":"Perri","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib1155","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1245\/s10434-011-2100-x","article-title":"Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer","volume":"19","author":"Rauh-Hain","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.gofs.2019.01.003_bib1160","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1245\/s10434-014-4329-7","article-title":"Prognostic and predictive value of the peritoneal cancer index in primary advanced epithelial ovarian cancer patients after complete cytoreductive surgery: study of tumor bank ovarian cancer","volume":"22","author":"Gasimli","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.gofs.2019.01.003_bib1165","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1634\/theoncologist.2015-0239","article-title":"Advanced ovarian cancer: primary or interval debulking? Five categories of patients in view of the results of randomized trials and tumor biology: primary debulking surgery and interval debulking surgery for advanced ovarian cancer","volume":"21","author":"Makar","year":"2016","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.gofs.2019.01.003_bib1170","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/IGC.0b013e3181d6de1d","article-title":"Systematic lymphadenectomy for survival in epithelial ovarian cancer: a meta-analysis","volume":"20","author":"Kim","year":"2010","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"10.1016\/j.gofs.2019.01.003_bib1175","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/jjco\/hyw068","article-title":"The effect of lymphadenectomy on survival and recurrence in patients with ovarian cancer: a systematic review and meta-analysis","volume":"46","author":"Zhou","year":"2016","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib1180","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/jjco\/hyu175","article-title":"Systematic lymphadenectomy in the treatment of epithelial ovarian cancer: a meta-analysis of multiple epidemiology studies","volume":"45","author":"Gao","year":"2015","journal-title":"Jpn J Clin Oncol"},{"issue":"8","key":"10.1016\/j.gofs.2019.01.003_bib1185","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/jnci\/dji102","article-title":"Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial","volume":"97","author":"Panici","year":"2005","journal-title":"J Natil Canc Inst"},{"issue":"10","key":"10.1016\/j.gofs.2019.01.003_bib1190","first-page":"5503","article-title":"Impact of pelvic and para-aortic lymphadenectomy in advanced ovarian cancer after neoadjuvant chemotherapy","volume":"35","author":"Schwartz","year":"2015","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.gofs.2019.01.003_bib1195","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1016\/j.ajog.2006.06.068","article-title":"Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer","volume":"195","author":"Aletti","year":"2006","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib1200","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0020-7292(95)80014-X","article-title":"Lymphadenectomy in stage-III serous cystadenocarcinoma of the ovary","volume":"51","author":"Fukasawa","year":"1995","journal-title":"Int J Gynaecol Obstet"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib1205","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1006\/gyno.1995.1059","article-title":"Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival","volume":"56","author":"Scarabelli","year":"1995","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.gofs.2019.01.003_bib1210","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1245\/s10434-012-2400-9","article-title":"Systematic pelvic and aortic lymphadenectomy in advanced ovarian cancer patients at the time of interval debulking surgery: a double-institution case-control study","volume":"19","author":"Fagotti","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.gofs.2019.01.003_bib1215","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.5500","article-title":"LION: lymphadenectomy in ovarian neoplasms \u2013 A prospective randomized AGO study group led gynecologic cancer intergroup trial","volume":"35","author":"Harter","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib1220","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/jso.21940","article-title":"Surgical implications of mesenteric lymph node metastasis from advanced ovarian cancer after bowel resection","volume":"104","author":"Baiocchi","year":"2011","journal-title":"J Surg Oncol"},{"issue":"7","key":"10.1016\/j.gofs.2019.01.003_bib1225","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1245\/s10434-014-3558-0","article-title":"Mesenteric lymph node involvement in advanced ovarian cancer patients undergoing rectosigmoid resection: prognostic role and clinical considerations","volume":"21","author":"Gallotta","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.003_bib1230","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejso.2011.10.006","article-title":"Prognostic factors for and prognostic value of mesenteric lymph node involvement in advanced-stage ovarian cancer","volume":"38","author":"Gouy","year":"2012","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"10.1016\/j.gofs.2019.01.003_bib1235","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1245\/s10434-007-9565-7","article-title":"Surgical management of mesenteric lymph node metastasis in patients undergoing rectosigmoid colectomy for locally advanced ovarian carcinoma","volume":"14","author":"Salani","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib1240","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/IGC.0000000000000041","article-title":"Prognostic relevance of celiac lymph node involvement in ovarian cancer","volume":"24","author":"Mart\u00ednez","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10.1016\/j.gofs.2019.01.003_bib1245","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1245\/s10434-015-5051-9","article-title":"What should we expect after a complete cytoreduction at the time of interval or primary debulking surgery in advanced ovarian cancer?","volume":"23","author":"Chiva","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.003_bib1250","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ygyno.2006.11.002","article-title":"Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction","volume":"104","author":"Bristow","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2019.01.003_bib1255","article-title":"Interval debulking surgery for advanced epithelial ovarian cancer","volume":"1","author":"Tangjitgamol","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.gofs.2019.01.003_bib1260","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.01.017","article-title":"Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome","volume":"59","author":"Fagotti","year":"2016","journal-title":"Eur J Cancer"},{"issue":"9990","key":"10.1016\/j.gofs.2019.01.003_bib1265","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.gofs.2019.01.003_bib1270","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.05.017","volume":"64","author":"Onda","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.gofs.2019.01.003_bib1505","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer?","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.gofs.2019.01.003_bib1280","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2016.71.0723","article-title":"Value of neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer: a european perspective","volume":"35","author":"Fotopoulou","year":"2017","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.gofs.2019.01.003_bib1285","doi-asserted-by":"crossref","first-page":"8802","DOI":"10.1200\/JCO.2005.02.1287","article-title":"Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1\u00a0Trial","volume":"23","author":"Crawford","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.003_bib1290","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ygyno.2013.08.014","article-title":"Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy","volume":"131","author":"Greimel","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"15","key":"10.1016\/j.gofs.2019.01.003_bib1295","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1016\/j.ejca.2013.06.013","article-title":"Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971\u00a0randomised trial","volume":"49","author":"van Meurs","year":"2013","journal-title":"Eur J Cancer"},{"issue":"24","key":"10.1016\/j.gofs.2019.01.003_bib1300","doi-asserted-by":"crossref","first-page":"5605","DOI":"10.1200\/JCO.2005.08.147","article-title":"Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study","volume":"23","author":"Wenzel","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.gofs.2019.01.003_bib1305","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.21873\/anticanres.11050","article-title":"Impact of neoadjuvant chemotherapy on the rate of bowel resection in advanced epithelial ovarian cancer","volume":"36","author":"Philip","year":"2016","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.gofs.2019.01.003_bib1310","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.3802\/jgo.2017.28.e48","article-title":"Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer","volume":"28","author":"Lim","year":"2017","journal-title":"J Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib1315","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2016.01.008","article-title":"Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center","volume":"140","author":"Mueller","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib1320","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ygyno.2016.12.017","article-title":"Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer","volume":"144","author":"Kessous","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib1325","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2016.04.025","article-title":"Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: a national cancer database analysis","volume":"142","author":"Rauh-Hain","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.gofs.2019.01.003_bib1330","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000449203","article-title":"Does the number of neoadjuvant chemotherapy cycles before interval debulking surgery influence survival in advanced ovarian cancer?","volume":"91","author":"Akladios","year":"2016","journal-title":"Oncology"},{"issue":"6","key":"10.1016\/j.gofs.2019.01.003_bib1335","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1701-2163(16)35272-0","article-title":"Optimal debulking targets in women with advanced stage ovarian cancer: a retrospective study of immediate versus interval debulking surgery","volume":"34","author":"Altman","year":"2012","journal-title":"J Obstet Gynaecol Can"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib1340","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00404-015-3813-z","article-title":"Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer","volume":"293","author":"Bian","year":"2016","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib1345","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2011.08.014","article-title":"An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)","volume":"124","author":"Chi","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.gofs.2019.01.003_bib1350","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1097\/IGC.0000000000000241","article-title":"Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?","volume":"24","author":"Markauskas","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib1355","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/IGC.0b013e3182013e2f","article-title":"Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer","volume":"21","author":"Milam","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.gofs.2019.01.003_bib1360","first-page":"777","article-title":"Treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective study","volume":"17","author":"Rafii","year":"2007","journal-title":"Int J GynecolCancer"},{"issue":"8","key":"10.1016\/j.gofs.2019.01.003_bib1370","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1097\/IGC.0000000000000517","article-title":"Multiple cycles of neoadjuvant chemotherapy associated with poor survival in bulky stage IIIC and IV ovarian cancer","volume":"25","author":"Ren","year":"2015","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.003_bib1375","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.clon.2006.11.015","article-title":"The neoadjuvant approach in the treatment of patients with advanced epithelial ovarian carcinoma","volume":"19","author":"Rosa","year":"2007","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib1445","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ygyno.2014.07.004","article-title":"The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer","volume":"134","author":"Rosen","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.gofs.2019.01.003_bib1450","first-page":"1331","article-title":"Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis","volume":"20","author":"Sehouli","year":"2010","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib1455","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2017.02.023","article-title":"Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?","volume":"145","author":"Sioulas","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.003_bib1440","first-page":"580","article-title":"Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?","volume":"20","author":"Solmaz","year":"2015","journal-title":"J BUON"},{"issue":"Suppl. 1","key":"10.1016\/j.gofs.2019.01.003_bib1460","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ijgc-00009577-200602001-00008","article-title":"A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer","volume":"16","author":"Steed","year":"2006","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.003_bib1465","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1245\/s10434-013-3278-x","article-title":"Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum\/taxane-based chemotherapy and late interval debulking surgery","volume":"21","author":"Stoeckle","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.gofs.2019.01.003_bib1470","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00404-013-2924-7","article-title":"Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer","volume":"288","author":"Taskin","year":"2013","journal-title":"Arch Gynecol Obstet"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib1475","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ygyno.2011.08.030","article-title":"Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer","volume":"123","author":"Thrall","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"14","key":"10.1016\/j.gofs.2019.01.003_bib1480","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.ejca.2012.01.031","article-title":"Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?","volume":"48","author":"Trope","year":"2012","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.gofs.2019.01.003_bib1485","first-page":"564","article-title":"Systemic chemotherapy \u2013 Before or after radical surgery in treatment of patients with advanced ovarian carcinoma?","volume":"31","author":"Zamurovic","year":"2010","journal-title":"Eur J Gynaecol Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.003_bib1490","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ygyno.2014.09.002","article-title":"Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer","volume":"135","author":"Colombo","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.003_bib1495","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ygyno.2013.12.002","article-title":"Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: safety and effectiveness","volume":"132","author":"da Costa Miranda","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.003_bib1390","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ejogrb.2011.07.014","article-title":"Optimal timing of interval debulking surgery in advanced ovarian cancer: yet to be defined?","volume":"159","author":"Stoeckle","year":"2011","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.003_bib1500","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00404-016-4256-x","article-title":"The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc\u2013IV high-grade serous ovarian cancer","volume":"295","author":"Xu","year":"2017","journal-title":"Arch Gynecol Obstet"},{"issue":"4","key":"10.1016\/j.gofs.2019.01.003_bib1385","first-page":"2315","article-title":"Initial incomplete surgery modifies prognosis in advanced ovarian cancer regardless of subsequent management","volume":"35","author":"Bacalbasa","year":"2015","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib1395","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000381462","article-title":"Oncologic concerns regarding laparoscopic cytoreductive surgery in patients with advanced ovarian cancer submitted to neoadjuvant chemotherapy","volume":"89","author":"Favero","year":"2015","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib1400","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2016.08.030","article-title":"Laparoscopic staging for apparent stage I epithelial ovarian cancer","volume":"216","author":"Melamed","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib1405","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/IGC.0000000000000096","article-title":"Comparison of perioperative outcomes and complication rates between conventional versus robotic-assisted laparoscopy in the evaluation and management of early, advanced, and recurrent stage ovarian, fallopian tube, and primary peritoneal cancer","volume":"24","author":"Nezhat","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"10.1016\/j.gofs.2019.01.003_bib1410","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/IGC.0000000000000491","article-title":"Laparoscopic debulking surgery in the management of advanced ovarian cancer after neoadjuvant chemotherapy","volume":"25","author":"Corrado","year":"2015","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.003_bib1380","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ygyno.2011.06.020","article-title":"Laparoscopic-assisted cytoreduction for primary advanced ovarian cancer: success, morbidity and survival","volume":"123","author":"Fanning","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.gofs.2019.01.003_bib1415","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2015.10.922","article-title":"Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study","volume":"214","author":"Gueli Alletti","year":"2016","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib1420","doi-asserted-by":"crossref","first-page":"S952","DOI":"10.1245\/s10434-015-4651-8","article-title":"Neoadjuvant chemotherapy followed by maintenance therapy with or without bevacizumab in unresectable high-grade serous ovarian cancer: a case-control study","volume":"22","author":"Petrillo","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.003_bib1425","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejso.2010.10.004","article-title":"Morbidity of diaphragmatic surgery for advanced ovarian cancer: retrospective study of 148\u00a0cases","volume":"37","author":"Ch\u00e9reau","year":"2011","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"10.1016\/j.gofs.2019.01.003_bib1430","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1245\/ASO.2006.08.021","article-title":"A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study","volume":"13","author":"Fagotti","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.003_bib1435","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ygyno.2008.04.042","article-title":"External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: clues for a simplified score","volume":"110","author":"Brun","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.003_bib1510","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2009.10.856","article-title":"Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer","volume":"202","author":"Ch\u00e9reau","year":"2010","journal-title":"Am J Obstet Gynecol"}],"container-title":["Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468718919300030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468718919300030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:37:59Z","timestamp":1762853879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468718919300030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":150,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S2468718919300030"],"URL":"https:\/\/doi.org\/10.1016\/j.gofs.2019.01.003","relation":{},"ISSN":["2468-7189"],"issn-type":[{"value":"2468-7189","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chirurgie des cancers avanc\u00e9s de l\u2019ovaire. Article r\u00e9dig\u00e9 sur la base de la recommandation nationale de bonnes pratiques cliniques en canc\u00e9rologie intitul\u00e9e \u00ab\u00a0Conduites \u00e0 tenir initiales devant des patientes atteintes d\u2019un cancer \u00e9pith\u00e9lial de l\u2019ovaire\u00a0\u00bb \u00e9labor\u00e9e par FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY sous l\u2019\u00e9gide du CNGOF et labellis\u00e9e par l\u2019INCa","name":"articletitle","label":"Article Title"},{"value":"Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gofs.2019.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}